IQV
Price
$208.05
Change
+$0.73 (+0.35%)
Updated
Jul 24 closing price
Capitalization
34.72B
2 days until earnings call
Intraday BUY SELL Signals
RVTY
Price
$110.47
Change
-$2.70 (-2.39%)
Updated
Jul 24 closing price
Capitalization
12.32B
9 days until earnings call
Intraday BUY SELL Signals
TMO
Price
$568.26
Change
-$4.06 (-0.71%)
Updated
Jul 24 closing price
Capitalization
211.18B
94 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IQV or RVTY or TMO

IQV vs RVTY vs TMO Comparison Chart in %
View a ticker or compare two or three
Jul 20, 2026

Which Stock Would AI Choose? IQVIA (IQV) vs. Revvity (RVTY) vs. Thermo Fisher Scientific (TMO) Stock Comparison

Key Takeaways

  • IQVIA (IQV), Revvity (RVTY), and Thermo Fisher Scientific (TMO) operate in overlapping life sciences and healthcare services sectors but differ in business models, with IQVIA focused on clinical research and data analytics, Revvity on life science tools and diagnostics, and Thermo Fisher Scientific on broader instrumentation and lab solutions.
  • Year-to-date through mid-July 2026, RVTY posted stronger returns around 14% compared to IQV near 9%, while TMO showed recovery momentum amid sector rotation.
  • IQV faces near-term catalyst with second-quarter 2026 earnings scheduled for July 28, supported by a robust backlog and prior raised earnings-per-share guidance.
  • RVTY delivered an earnings-per-share beat in its first-quarter 2026 report despite a slight revenue shortfall, contributing to mixed short-term price action.
  • TMO benefited from signs of stabilizing lab spending and biotech funding, with notable weekly gains observed in prior months.
  • Relative positioning reflects trade-offs in growth drivers, with each stock showing varying sensitivity to healthcare spending trends and market sentiment in recent weeks.

Introduction

Investors and traders seeking exposure to the life sciences and healthcare sectors often evaluate IQVIA (IQV), Revvity (RVTY), and Thermo Fisher Scientific (TMO) together due to their interconnected roles in clinical development, diagnostics, and laboratory infrastructure. These companies provide complementary services and products that support pharmaceutical research, testing, and commercialization. The comparison is particularly relevant for those monitoring sector rotation, earnings momentum, and relative valuation in a market environment influenced by biotech funding and healthcare utilization trends. This analysis highlights observable performance metrics, business positioning, and recent developments to inform a balanced assessment of their market standing.

IQV Overview and Recent Performance

IQVIA Holdings Inc. (IQV) delivers clinical research services, commercial insights, and healthcare intelligence primarily to life sciences and healthcare clients. In recent market activity, the stock has shown resilience amid broader sector movements, with year-to-date returns approaching 9% through mid-July 2026. Positive sentiment has been supported by a strong backlog and an upward revision to adjusted earnings-per-share outlook announced in late June. The company is scheduled to report second-quarter 2026 results on July 28, which market participants are watching for further confirmation of organic growth trends. Recent weeks have featured analyst upgrades and focus on the firm’s data analytics capabilities as a differentiator in clinical development efficiency.

RVTY Overview and Recent Performance

Revvity Inc. (RVTY) provides life science tools, reagents, and diagnostics solutions across research and applied markets. Through mid-July 2026, the stock recorded year-to-date gains near 14%, outpacing some peers in the period. Following first-quarter 2026 results released in early May, which featured an earnings-per-share beat alongside a modest revenue shortfall, price action remained mixed with short-term declines noted in subsequent weeks. Recent market activity reflects ongoing evaluation of demand for its portfolio amid fluctuating research spending patterns. The company continues to emphasize strategic portfolio adjustments to align with evolving customer needs in diagnostics and life sciences applications.

TMO Overview and Recent Performance

Thermo Fisher Scientific Inc. (TMO) offers a wide range of scientific instruments, reagents, and laboratory services supporting research, diagnostics, and biopharma production. In recent market activity, the stock demonstrated recovery momentum, including notable weekly gains observed around late May amid signs of improving lab spending and biotech funding conditions. Year-to-date performance has aligned with sector peers, with emphasis on its scale and diversified exposure to instrumentation and services. Recent weeks have highlighted comparisons with other life sciences tools providers as investors assess stabilization in customer capital expenditure trends.

Trending AI Robots

Tickeron maintains a curated selection of AI trading bots on its Trending AI Robots page. The platform offers hundreds of AI Trading Bots capable of trading thousands of different tickers, yet only those demonstrating the strongest alignment with prevailing market conditions receive placement in this trending section. Available bots span a range of trading styles, strategies, timeframes, performance metrics, and ticker sets, with historical statistics varying widely across the library. Users can review detailed performance data and suitability indicators directly on the page to identify options matching specific objectives.

Head-to-Head Comparison

IQVIA (IQV) centers on outsourced clinical research and data services, creating exposure to pharmaceutical development pipelines and regulatory timelines, whereas Revvity (RVTY) emphasizes specialized tools and diagnostics with sensitivity to research budgets. Thermo Fisher Scientific (TMO) offers broader instrumentation and end-to-end lab solutions, providing scale advantages but greater correlation to capital spending cycles. Recent momentum has favored RVTY on a year-to-date basis, while IQV benefits from a visible earnings catalyst and TMO from sector recovery signals. Risk factors include healthcare policy changes and funding volatility for all three, though business model differences create distinct valuation sensitivities: service-oriented exposure for IQV, product mix for RVTY, and hardware/services balance for TMO. Market sentiment in recent weeks has reflected rotation toward companies with clear backlog visibility or spending stabilization.

Tickeron AI Verdict

Based on observable trend consistency, backlog strength, and relative positioning ahead of earnings, Tickeron’s AI would currently assign a modestly higher probability of favorable near-term momentum to IQV among the three, while noting that RVTY and TMO present competitive trade-offs depending on sector spending recovery breadth. All assessments remain probabilistic and subject to evolving market data.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2026
Stock price -- (IQV: $208.05RVTY: $110.47TMO: $568.26)
Brand notoriety: RVTY and TMO are not notable and IQV is notable
The three companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: IQV: 72%, RVTY: 76%, TMO: 127%
Market capitalization -- IQV: $34.72B, RVTY: $12.32B, TMO: $211.18B
$IQV is valued at $34.72B, while RVTY has a market capitalization of $12.32B, and TMO's market capitalization is $211.18B. The market cap for tickers in this @Medical Specialties ranges from $3.82T to $0. The average market capitalization across the @Medical Specialties industry is $17.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IQV’s FA Score shows that 0 FA rating(s) are green whileRVTY’s FA Score has 2 green FA rating(s), and TMO’s FA Score reflects 1 green FA rating(s).

  • IQV’s FA Score: 0 green, 5 red.
  • RVTY’s FA Score: 2 green, 3 red.
  • TMO’s FA Score: 1 green, 4 red.
According to our system of comparison, TMO is a better buy in the long-term than RVTY, which in turn is a better option than IQV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IQV’s TA Score shows that 6 TA indicator(s) are bullish while RVTY’s TA Score has 4 bullish TA indicator(s), and TMO’s TA Score reflects 6 bullish TA indicator(s).

  • IQV’s TA Score: 6 bullish, 3 bearish.
  • RVTY’s TA Score: 4 bullish, 5 bearish.
  • TMO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, IQV is a better buy in the short-term than TMO, which in turn is a better option than RVTY.

Price Growth

IQV (@Medical Specialties) experienced а +0.87% price change this week, while RVTY (@Medical Specialties) price change was +0.29% , and TMO (@Medical Specialties) price fluctuated +6.72% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.

Reported Earning Dates

IQV is expected to report earnings on Jul 28, 2026.

RVTY is expected to report earnings on Aug 04, 2026.

TMO is expected to report earnings on Oct 28, 2026.

Industries' Descriptions

@Medical Specialties (-1.55% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TMO($211B) has a higher market cap than IQV($34.7B) and RVTY($12.3B). RVTY has higher P/E ratio than TMO and IQV: RVTY (53.11) vs TMO (30.58) and IQV (25.84). RVTY YTD gains are higher at: 14.411 vs. TMO (-1.736) and IQV (-7.702). TMO has higher annual earnings (EBITDA): 11.7B vs. IQV (3.52B) and RVTY (773M). RVTY has less debt than IQV and TMO: RVTY (3.35B) vs IQV (16.1B) and TMO (43.2B). TMO has higher revenues than IQV and RVTY: TMO (45.2B) vs IQV (16.6B) and RVTY (2.9B).
IQVRVTYTMO
Capitalization34.7B12.3B211B
EBITDA3.52B773M11.7B
Gain YTD-7.70214.411-1.736
P/E Ratio25.8453.1130.58
Revenue16.6B2.9B45.2B
Total Cash2.1BN/A1.12B
Total Debt16.1B3.35B43.2B
FUNDAMENTALS RATINGS
IQV vs RVTY vs TMO: Fundamental Ratings
IQV
RVTY
TMO
OUTLOOK RATING
1..100
857937
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
15
Undervalued
12
Undervalued
PROFIT vs RISK RATING
1..100
10010080
SMR RATING
1..100
428962
PRICE GROWTH RATING
1..100
434542
P/E GROWTH RATING
1..100
622837
SEASONALITY SCORE
1..100
65n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TMO's Valuation (12) in the Medical Specialties industry is in the same range as RVTY (15) in the Medical Specialties industry, and is somewhat better than the same rating for IQV (65) in the Servicestothe Health Industry industry. This means that TMO's stock grew similarly to RVTY’s and somewhat faster than IQV’s over the last 12 months.

TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as RVTY (100) in the Medical Specialties industry, and is in the same range as IQV (100) in the Servicestothe Health Industry industry. This means that TMO's stock grew similarly to RVTY’s and similarly to IQV’s over the last 12 months.

IQV's SMR Rating (42) in the Servicestothe Health Industry industry is in the same range as TMO (62) in the Medical Specialties industry, and is somewhat better than the same rating for RVTY (89) in the Medical Specialties industry. This means that IQV's stock grew similarly to TMO’s and somewhat faster than RVTY’s over the last 12 months.

TMO's Price Growth Rating (42) in the Medical Specialties industry is in the same range as IQV (43) in the Servicestothe Health Industry industry, and is in the same range as RVTY (45) in the Medical Specialties industry. This means that TMO's stock grew similarly to IQV’s and similarly to RVTY’s over the last 12 months.

RVTY's P/E Growth Rating (28) in the Medical Specialties industry is in the same range as TMO (37) in the Medical Specialties industry, and is somewhat better than the same rating for IQV (62) in the Servicestothe Health Industry industry. This means that RVTY's stock grew similarly to TMO’s and somewhat faster than IQV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IQVRVTYTMO
RSI
ODDS (%)
Bearish Trend 3 days ago
56%
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
61%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
63%
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
60%
Momentum
ODDS (%)
Bullish Trend 3 days ago
64%
Bearish Trend 3 days ago
71%
Bullish Trend 3 days ago
59%
MACD
ODDS (%)
Bearish Trend 3 days ago
50%
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
66%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
61%
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
61%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
63%
Bullish Trend 3 days ago
61%
Bullish Trend 3 days ago
61%
Advances
ODDS (%)
Bullish Trend 3 days ago
60%
Bullish Trend 4 days ago
64%
Bullish Trend 4 days ago
61%
Declines
ODDS (%)
Bearish Trend 5 days ago
65%
Bearish Trend 7 days ago
67%
Bearish Trend 6 days ago
63%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
66%
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
63%
Aroon
ODDS (%)
Bullish Trend 3 days ago
57%
Bullish Trend 3 days ago
64%
Bullish Trend 3 days ago
59%
View a ticker or compare two or three
Interact to see
Advertisement
IQV
Daily Signal:
Gain/Loss:
RVTY
Daily Signal:
Gain/Loss:
TMO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
INEO0.760.04
+5.15%
INNEOVA Holdings Limited
CVCO569.777.67
+1.36%
Cavco Industries
ED113.010.22
+0.20%
Consolidated Edison
KURA10.39-0.06
-0.57%
Kura Oncology
MENS2.36-0.35
-12.92%
Jyong Biotech Ltd

IQV and

Correlation & Price change

A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IQV
1D Price
Change %
IQV100%
+0.35%
CRL - IQV
75%
Closely correlated
-1.18%
TMO - IQV
71%
Closely correlated
-0.71%
MEDP - IQV
65%
Loosely correlated
-0.73%
RVTY - IQV
64%
Loosely correlated
-2.39%
A - IQV
62%
Loosely correlated
-0.84%
More